Aegis Sciences Corporation published definitive testing results for compounds to assess adherence with prescribed drugs and recent exposure to illicit compounds.
Public source
Publisher name
Public post
Definitive testing results for each of these compounds help clinicians assess adherence with prescribed drugs and recent exposure to illicit compounds. The Aegis clinica…
Company
Aegis Sciences Corporation
Helping Clinicians Make Better Decisions
- Industry
- Hospitals and Health Care
- Location
- Nashville, US
- Company size
- 501–1,000 employees
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation is a forensic toxicology and healthcare laboratory that provides science-driven drug testing and consulting services based in Nashville, TN. Aegis healthcare testing services are designed for the unique needs of healthcare specialties in the areas of Pain Management, Behavioral and Mental Health, Substance Use Disorder, Prenatal Care, and Chronic Disease Management. Aegis delivers evidence-based, clinically actionable information related to medication compliance, substance abuse, and drug-drug interactions through definitive testing. Since 2020, Aegis Sciences Corporation has led the industry in Novel Psychoactive Substance (NPS) testing, empowering clinicians with bi-annual test menu updates aligned with the latest recommendations from the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologists (SOFT) to support informed, evidence-based care. In addition to toxicology testing services, Aegis offers sports anti-doping and forensic testing services to professional and amateur sports organizations, college, and university athletic programs. Aegis also provides molecular diagnostic testing, clinical trial support, and other testing services. For more information please visit http://www.aegislabs.com/.
See moreLatest activity
Latest activity from Aegis Sciences Corporation
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
FDB (First Databank, Inc.)
FDB (First Databank, Inc.) published a new study in The Pharmacogenomics Journal sequencing the genomes of 210 ICU patients and checking them against five ICU drugs
Research & Knowledge
ElixirTrials, Inc.
ElixirTrials, Inc. published the next installment of the ElixirTrials series Clinical Trials: The Public Perspective, in which Ashton discussed expanding access to clinical trials.
Research & Knowledge
Opioid Clinical Management Inc
Opioid Clinical Management Inc found that 75% of patients entering treatment for opioid addiction reported their opioid use began with a valid prescription from a physician, validated by the NIH.
Research & Knowledge
Mito Health
Mito Health published a post detailing what a high creatine kinase result means, when to retest, and which symptoms are urgent.
Research & Knowledge
Avalon Healthcare Solutions